Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hydroxychloroquine

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education Global

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

WHO publishes new infodemic management tools for pandemic preparedness

The taxonomy will support pandemic planning for respiratory pathogen disease events

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

AstraZeneca studies highlight burden of COVID-19 for immunocompromised

The risk of hospitalisation due to COVID-19 was 14 times greater for IC individuals

- PMLiVE

Differences in immune responses could optimise future COVID-19 vaccines

Vulnerability to different mutations was linked to previous infections and vaccination

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

New vaccine technology could help fight future viruses and variants

The antigen technology could enhance vaccine protection against potential threats

- PMLiVE

Novavax’s updated COVID-19 vaccine approved by FDA for emergency use

Individuals aged 12 years and older will be eligible to receive the company's updated vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links